Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma : Post hoc analysis of TRIUMPH study
Copyright © 2024 Elsevier Ltd. All rights reserved..
OBJECTIVES: This study aimed to investigate whether genetic alterations in PI3KCA and the cell cycle pathways influence the efficacy of durvalumab, an immune checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) who had previously failed platinum-based treatment.
MATERIALS AND METHODS: We obtained data from a phase II umbrella trial of patients with HNSCC who failed platinum-based treatment (TRIUMPH, NCT03292250). Patients receiving durvalumab treatment comprised those with PIK3CA alterations (Group A), those with cell cycle pathway alterations such as CDKN2A (Group B), and those with no druggable genetic alterations (Group C). We analyzed the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in each group and evaluated the potential predictive factors for durvalumab.
RESULTS: We analyzed the data of 87 patients: 18, 12, and 57 in groups A, B, and C, respectively. The ORRs were 27.8 %, 8.3 %, and 15.8 % in Groups A, B, and C, respectively (P = 0.329), and the median PFS for each group was 2.3, 1.6, and 1.7 months, respectively, with no significant differences between the groups (P = 0.24). Notably, patients with lower neutrophil-lymphocyte ratio (NLR) (≤5.8) had longer PFS (median, 2.8 vs 1.6 months, P < 0.001), while those with lower platelet-lymphocyte ratio (PLR) (≤491.2) exhibited longer PFS (median, 1.8 vs 1.2 months, P < 0.001).
CONCLUSION: Durvalumab's efficacy was similar, irrespective of the presence of PIK3CA or cell cycle pathway genetic alterations in patients with platinum-resistant HNSCC. The NLR and PLR may be promising predictive biomarkers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Oral oncology - 151(2024) vom: 30. Apr., Seite 106739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Dong Hyun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2024.106739 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369477782 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369477782 | ||
| 003 | DE-627 | ||
| 005 | 20240410232631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2024.106739 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM369477782 | ||
| 035 | |a (NLM)38458039 | ||
| 035 | |a (PII)S1368-8375(24)00057-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Dong Hyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma |b Post hoc analysis of TRIUMPH study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: This study aimed to investigate whether genetic alterations in PI3KCA and the cell cycle pathways influence the efficacy of durvalumab, an immune checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) who had previously failed platinum-based treatment | ||
| 520 | |a MATERIALS AND METHODS: We obtained data from a phase II umbrella trial of patients with HNSCC who failed platinum-based treatment (TRIUMPH, NCT03292250). Patients receiving durvalumab treatment comprised those with PIK3CA alterations (Group A), those with cell cycle pathway alterations such as CDKN2A (Group B), and those with no druggable genetic alterations (Group C). We analyzed the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in each group and evaluated the potential predictive factors for durvalumab | ||
| 520 | |a RESULTS: We analyzed the data of 87 patients: 18, 12, and 57 in groups A, B, and C, respectively. The ORRs were 27.8 %, 8.3 %, and 15.8 % in Groups A, B, and C, respectively (P = 0.329), and the median PFS for each group was 2.3, 1.6, and 1.7 months, respectively, with no significant differences between the groups (P = 0.24). Notably, patients with lower neutrophil-lymphocyte ratio (NLR) (≤5.8) had longer PFS (median, 2.8 vs 1.6 months, P < 0.001), while those with lower platelet-lymphocyte ratio (PLR) (≤491.2) exhibited longer PFS (median, 1.8 vs 1.2 months, P < 0.001) | ||
| 520 | |a CONCLUSION: Durvalumab's efficacy was similar, irrespective of the presence of PIK3CA or cell cycle pathway genetic alterations in patients with platinum-resistant HNSCC. The NLR and PLR may be promising predictive biomarkers | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell cycle pathway | |
| 650 | 4 | |a Durvalumab | |
| 650 | 4 | |a Head and neck squamous cell carcinoma | |
| 650 | 4 | |a Neutrophil-lymphocyte ratio | |
| 650 | 4 | |a PI3KCA | |
| 650 | 4 | |a Platelet-lymphocyte ratio | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a durvalumab |2 NLM | |
| 650 | 7 | |a 28X28X9OKV |2 NLM | |
| 650 | 7 | |a PIK3CA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Lim, Seung Taek |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hye Ryun |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Eun Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Hee Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yun-Gyoo |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Der Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Jung Hye |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang-Cheol |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hyun Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Kyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Keam, Bhumsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Keon-Uk |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Seong-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Yun, Hwan Jung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 151(2024) vom: 30. Apr., Seite 106739 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2024 |g day:30 |g month:04 |g pages:106739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2024.106739 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2024 |b 30 |c 04 |h 106739 | ||